	US 11,717,493 B2
	Cannabidiol compositions for the treatment of inflammation
Aaron Michael Schneider, Houston, TX (US)
Assigned to RevRx, LLC, Houston, TX (US)
Filed by RevRx, LLC, Houston, TX (US)
Filed on Jul. 17, 2020, as Appl. No. 16/932,164.
Claims priority of provisional application 62/876,143, filed on Jul. 19, 2019.
Prior Publication US 2021/0015763 A1, Jan. 21, 2021
Int. Cl. A61K 36/00 (2006.01); A61K 31/05 (2006.01); A61K 31/045 (2006.01); A61K 31/125 (2006.01); A61P 29/00 (2006.01); A61K 36/28 (2006.01); A61K 36/324 (2006.01); A61K 47/10 (2017.01)

CPC A61K 31/05 (2013.01) [A61K 31/045 (2013.01); A61K 31/125 (2013.01); A61K 36/28 (2013.01); A61K 36/324 (2013.01); A61K 47/10 (2013.01); A61P 29/00 (2018.01)]

19 Claims

1. A method of treating inflammation and pain comprising:

administering to a subject in need thereof an effective amount of a composition wherein the composition comprises:

hemp cannabidiol, wherein an amount of hemp cannabidiol is 3.5-8.5 mg/ml;

menthol, wherein an amount of menthol is 2.0-4.0 weight percent (wt %);

an herb extract of arnica montana, wherein an amount of the arnica montana herb extract is 1.0-5.0 wt %;

an herb extract of Boswellia serrata wherein an amount of the Boswellia serrata herb extract is 1.0 to 3.0 wt %;

glycerin; and

water, wherein the amount of hemp cannabidiol and menthol is synergistic for treating inflammation and pain, wherein the composition is free of any tetrahydrocannabinol.